With 30+ years of expertise executing full-service cardiometabolic trials involving more than 43,000 patients and over 3,320 sites globally, we’re well-equipped to support your drug development program. Our dedicated team offers strategic planning, protocol design, and robust capabilities for Phase I-IV cardiometabolic clinical trials, ensuring high patient retention rates and efficient development timelines.
Find out how our global network of key opinion leaders, partnerships with academic research organizations, and patient-centric approach can enhance your cardiovascular research efforts. Learn more in our fact sheet.